沙库巴曲缬沙坦治疗射血分数降低心力衰竭的临床现状

Clinical Status of Shakuba Qusarsartan in Treating Heart Failure by Ejecting Blood Fraction

沙库巴曲缬沙坦是首个上市的血管紧张素受体脑啡肽酶抑制剂(ARNI),具有双重作用机制,既可以抑制利钠肽系统(NPs)的分解,也可同时拮抗肾素-血管紧张素-醛固酮系统(RAAS);ARNI的问世自此开启了三类神经激素拮抗剂治疗心力衰竭的新篇章,改变了抑制RAAS系统和交感神经系统以预防和治疗心衰的传统常规格局。

Shakuba valsartan is the first marketed angiotensin receptor enkephalinase inhibitor(ARNI)with a dual mechanism of action that inhibits the breakdown of natriuretic peptide systems(NPs).Antagonizing the renin-angiotensin-aldosterone system(RAAS);the advent of ARNI has opened a new chapter in the treatment of heart failure with three classes of neurohormone antagonists,altering the inhibition of the RAAS system and the sympathetic nervous system to prevent and treat heart failure.Traditional conventional pattern.